Molecular docking studies of some benzoxazole and benzothiazole derivatives as VEGFR-2 target inhibitors: In silico design, MD simulation, pharmacokinetics and DFT studies

Abstract

Breast cancer, a deadly disease among women, demands effective interventions due to its global impact, with over one million annual cases. Current anti-breast cancer drugs displays several side effects, also most patients resists to these drugs during early treatment stage. Hence, global search for better drugs with less side effects became necessary. The objective of this study is to identify potential inhibitors of vascular endothelial growth factor receptor-2 (VEGFR-2), a critical target in breast cancer treatment. Molecular docking-based virtual screening of 45 benzoxazole/thiazole derivatives was conducted, followed by molecular dynamics simulations to explore ligandprotein interactions. Seven ligands (compounds 7, 10, 12, 13, 14, 20, and 26) demonstrated superior binding affinities ranging from -157.85 to -173.88 kcal/mol (MolDock scores) and -109.96 to -129.23 kcal/mol (Rerank scores) compared to Sorafenib (-156.35 kcal/mol MolDock score and -102.63 kcal/mol Re-rank score). Compound 7, identified as a potential hit, exhibited stability in a 100-ns dynamic simulation. It was chosen as a template for designing novel inhibitors, resulting in five compounds with improved binding affinities ranging from -177.84 to -184.69 kcal/mol (MolDock scores) and -137.34 to -143.44 kcal/mol (Re-rank scores). Pharmacological profiling confirmed the drug-like properties of both the potential hit molecules and the designed compounds, with 0–1 violations against Lipinski’s rule of five and favorable pharmacokinetics status. Density functional theory (DFT) studies illustrated the reactive nature of the designed compounds. These findings suggest the potential of these molecules as novel VEGFR-2 inhibitors for breast cancer treatment, providing promising prospects for future drug development.

Keywords

Breast cancer / Molecular docking / MD simulation / VEGFR-2 target / Benzoxazole and benzothiazole derivatives / Sorafenib

References

[1] GeW, HaoX, HanF, LiuZ, WangT, et al. Synthesis and structure-activity relationship studies of parthenolide derivatives as potential anti-triple negative breast cancer agents. Eur J Med Chem. 2019;166:445–469.

[2] BrayF, FerlayJ, SoerjomataramJ, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2018;68:394–424.

[3] NiuG, ChenX. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets. 2010;11(8):1000–1017.

[4] WangX, BoveAM, SimoneG, Ma B. Molecular bases of VEGFR-2-mediated physiological function and pathological role. Front Cell Dev Biol. 2020;8:599281.

[5] Abou-SeriSM, Eldehna WM, AliMM, AbouDM. 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: synthesis and in vitro biological evaluation. Eur J Med Chem.2015.

[6] AbdullahiSH, UzairuA, DanazumiAU, et al. Computational design of quinoxaline molecules as VEGFR-2 inhibitors: QSAR modeling, pharmacokinetics, molecular docking, and dynamics simulation studies. Biocatal Agric Biotechnol. 2023;51:102787.

[7] AbdullahiSH, UzairuA, ShallangwaGA, UbaS, UmarAB. Molecular docking, ADMET and pharmacokinetic properties predictions of some di-aryl pyridinamine derivatives as estrogen receptor (ER+) kinase inhibitors. Egyptian J Basic and Appl Sci. 2022a;9(1):180–204.

[8] ParamashivappaR, Phani Kumar P, Subba RaoPV, Srinivasa RaoA. Design, synthesis and biological evaluation of benzimidazole/benzothiazole and benzoxazole derivatives as cyclooxygenase inhibitors. Bioorg Med Chem Lett. 2003;13(4):657–660.

[9] AbdullahiSH, UzairuA, IbrahimMT, Umar BA. Chemoinformatics activity prediction, ligand-based drug design, molecular docking and pharmacokinetics studies of some series of 4, 6-diaryl-2-pyrimidinamine derivatives as anticancer agents. Bull Natl Res Cent. 2021;45(1):167.

[10] AbdullahiSH, UzairuA, ShallangwaGA, UbaS, UmarBA. In-silico activity prediction, structure-based drug design, molecular docking and pharmacokinetic studies of selected quinazoline derivatives for their antiproliferative activity against triple negative breast cancer (MDA-MB231) cell line. Bull Natl Res Cent. 2022b;46:2.

[11] AnusuyaS, Velmurugan D, GromihaMM. Identification of dengue viral RNA-dependent RNA polymerase inhibitor using computational fragment-based approaches and molecular dynamics study. J Biomol Struct Dynam. 2016;34(7):1512–1532.

[12] BenmansourF, EydouxC, QueratG, et al. Novel 2-phenyl-5-[(E)-2-(thiophen-2-yl) ethenyl]-1, 3, 4-oxadiazole and 3-phenyl-5-[(E)-2-(thiophen-2-yl)ethenyl]-1, 2, 4-oxadiazole derivatives as dengue virus inhibitors targeting NS5 polymerase. Eur J Med Chem. 2016;109:146–156.

[13] MengXY, ZhangHX, MezeiM, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011;7(2):146–157.

[14] AbdullahiSH, UzairuA, ShallangwaGA, UbaS, UmarAB. Structure-based design of some novel 3-methylquinoxaline derivatives through molecular docking and pharmacokinetics studies as novel VEGFR-2 inhibitors. Chemistry Africa.2022.

[15] AbdullahiSH, UzairuA, ShallangwaGA, UbaS, UmarAB. In-silico design of phthalazine derivatives as VEGFR-2 inhibitors: molecular docking and pharmacological profile studies. Advanced Journal of Chemistry, Section B. 2022;4(4):309–327.

[16] El-HelbyAG, SakrH, EissaIH, Abulkhair H, Al-KarmalawyAA, El-AdlK. Design, synthesis, molecular docking, and anticancer activity of benzoxazole derivatives as VEGFR-2 inhibitors. Archives of Pharmaceutical Chemistry and Life Sciences.2019.

[17] El-HelbyAG, SakrH, EissaIH, Abulkhair H, Al-KarmalawyAA, El-AdlK. Benzoxazole/benzothiazole derived VEGFR-2 inhibitors: design, synthesis, molecular docking, and anticancer evaluations. Archiv Pharmaceut Chem Life Sci. 2019. https://doi.org/10.1002/ardp.201900178.

[18] AbdullahiSH, UzairuA, ShallangwaGA, UbaS, UmarAB. Pharmacokinetic profiling of quinazoline-4(3H)-one analogs as EGFR inhibitors:3D-QSAR modeling, molecular docking studies and the design of therapeutic agents. J Taibah Univ Med Sci. 2023;18(5):1018–1029.

[19] HasegawaM, Nishigaki N, WashioY, et al. Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors. J Med Chem. 2007;50:4453–4470.

[20] Bitencourt-FerreiraG, de Azevedo JrWF. Molegro virtual docker for docking. Methods Mol Biol. 2019;2053:149–167.

[21] IbrahimZY, UzairuA, ShallangwaG, Abechi S. Molecular docking studies, drug-likeness, and in-silic. ADMET prediction of some novel β-Amino alcohol grafted 1, 4, 5-trisubstituted 1, 2, 3-triazoles derivatives as elevators of p53 protein levels. Scientific African. 2020;10:e00570.

[22] ThomsenR, Christensen MH. MolDock: a new technique for high accuracy molecular docking. J Med Chem. 2006;49(11):3315–3321.

[23] BappyMNI, RobinTB, PromeAA, et al. Subtractive proteomics analysis to uncover the potent drug targets for distinctive drug design of Candida auris. Heliyon. 2023;9(3):e09712.

[24] KhanamM, MoinAT, AhmedKA, et al. Computational modeling of potential milciclib derivatives inhibitor-CDK2 binding through global docking and accelerated molecular dynamics simulations. Inform Med Unlocked. 2022;33:101069.

[25] MoinAT, UllahMA, PatilRB, et al. A computational approach to design a polyvalent vaccine against human respiratory syncytial virus. Sci Rep. 2023;13(1):1–20.

[26] WangE, SunH, WangJ, et al. End-point binding free energy calculation with MM/PBSA and MM/GBSA: strategies and applications in drug design. Chem Rev. 2019;119:9478–9508.

[27] WaltersWP. Going further than Lipinski’s rule in drug design. Expet Opin Drug Discov. 2012;7:99–107.

[28] ArafY, MoinAT, TimofeevVI, et al. Immunoinformatic design of a multivalent peptide vaccine against mucormycosis: targeting FTR1 protein of major causative fungi. Front Immunol. 2022;13:863234.

[29] IbrahimMT, UzairuA. Theoretical validation of some third-generation epidermal growth factor receptor (EGFR) Inhibitors as non-small cell lung cancer (NSCLC) drugs. Egyptian J Basic and Appl Sci. 2023;10(1):329–341.

[30] AbdurrahmanS, RuslinR, HasanahAN, Mustarichie R. Molecular docking studies and ADME-tox prediction of phytocompounds from merremia peltata as a potential anti-alopecia treatment. J Adv Pharm Technol Research (JAPTR). 2021;12(2):132.

[31] TabtiK, HajjiH, SbaiA, Maghat H, BouachrineM, LakhlifiT. Identification of a potential thiazole inhibitor against biofilms by 3D QSAR, molecular docking, DFT analysis, MM-PBSA binding energy calculations, and molecular dynamics simulation. Phys Chem Res. 2023;11(2):369–389. https://doi.org/10.22036/pcr.2022.335657.2068.

[32] AliI, Rasheed MA, CavaluS, et al. Identification of natural lead compounds against hemagglutinin-esterase surface glycoprotein in human coronaviruses investigated via MD simulation, principal component analysis, cross-correlation, H-bond plot and MMGBSA. Biomedicines. 2023;11:793.

[33] TaskinD, Ozdemir M, YalcinB. LC-ESI-Tandem MS and in silico ADMET analysis of polyphenols from rhus coriaria L. And micromeria fruticosa (L.) druce Ssp. brachycalyx PH davis. Future J Pharmaceut Sci. 2021;7(1):1–11.

[34] UmarAB, UzairuA. Virtual screening, pharmacokinetic, and DFT studies of anticancer compounds as potential V600E-BRAF kinase inhibitors. J Taibah Univ Med Sci. 2023;18(5):933e946.

[35] UmarBA, UzairuA, ShallangwaGA, et al. Computational evaluation of potent 2 (1Himidazol-2-yl) pyridine derivatives as potential V600E-BRAF inhibitors. Egypt J Med Hum Genet. 2020;21(1):67.

[36] DainaA, Michielin O, ZoeteV. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1):42717.

[37] AhmedA, SaeedA, EjazSA, et al. Novel adamantyl clubbed iminothiazolidinones as promising elastase inhibitors: design, synthesis, molecular docking, ADMET DFT studies. RSC Adv. 2022;12(19):11974–11991.

[38] EdimMM, EnudiOC, AsuquoBB, et al. Aromaticity indices, electronic structural properties, and fuzzy atomic space investigations of naphthalene and its azaderivatives. Heliyon. 2021;7(2):e06138.

RIGHTS & PERMISSIONS

2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.